Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

539741

Sigma-Aldrich

PTP1B Inhibitor

PTP1B Inhibitor, CAS 765317-72-4, is a cell-permeable, selective, reversible and non-competitive allosteric inhibitor of PTP1B (IC₅₀ = 4 µM and 8 µM for PTP1B403 and PTP1B298, respectively).

Sinónimos:

PTP1B Inhibitor, 3-(3,5-Dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide, PTP Inhibitor XXII

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C26H19Br2N3O7S3
Número de CAS:
765317-72-4
Peso molecular:
741.45
Número MDL:
MFCD09037556
Código UNSPSC:
12352200
NACRES:
NA.77

Nivel de calidad

100

Ensayo

≥95% (HPLC)

Formulario

solid

fabricante / nombre comercial

Calbiochem®

condiciones de almacenamiento

OK to freeze
protect from light

color

white

solubilidad

DMSO: 100 mg/mL
ethanol: 5 mg/mL

Condiciones de envío

wet ice

temp. de almacenamiento

−20°C

cadena SMILES

[S](=O)(=O)(Nc5[s]ccn5)c1ccc(cc1)N[S](=O)(=O)c2cc3[o]c(c(c3cc2)C(=O)c4cc(c(c(c4)Br)O)Br)CC

InChI

1S/C26H19Br2N3O7S3/c1-2-21-23(24(32)14-11-19(27)25(33)20(28)12-14)18-8-7-17(13-22(18)38-21)41(36,37)30-15-3-5-16(6-4-15)40(34,35)31-26-29-9-10-39-26/h3-13,30,33H,2H2,1H3,(H,29,31)

Clave InChI

SXKBTDJJEQQEGE-UHFFFAOYSA-N

Descripción general

A cell-permeable, selective, reversible, and non-competitive allosteric inhibitor of PTP1B (IC50 = 4 µM and 8 µM for PTP1B403 and PTP1B298, respectively). Binds to a novel site away from the catalytic pocket and inhibits PTP1B activity by preventing closure of the WPD loop. Also available in InSolution format (Cat. No. 539749.

Acciones bioquímicas o fisiológicas

Cell permeable: yes
Primary Target
PTP1B403
Product does not compete with ATP.
Reversible: yes
Target IC50: 4 µM and 8 µM for PTP1B403 and PTP1B298, respectively

Envase

Packaged under inert gas

Advertencia

Toxicity: Standard Handling (A)

Reconstitución

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Otras notas

Wiesmann, C., et al. 2004. Nat. Struct. Mol. Biol.11, 730.

Información legal

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Vitor Ferreira et al.
Redox biology, 63, 102741-102741 (2023-05-26)
Olanzapine (OLA), a widely used second-generation antipsychotic (SGA), causes weight gain and metabolic alterations when administered orally to patients. Recently, we demonstrated that, contrarily to the oral treatment which induces weight gain, OLA administered via intraperitoneal (i.p.) in male mice
Sarah Zierold et al.
Journal of the American Heart Association, 10(6), e018322-e018322 (2021-03-06)
Background Brain-derived neurotrophic factor (BDNF) is expressed in neuronal and nonneuronal cells and may affect vascular functions via its receptor, tropomyosin-related kinase B (TrkB). In this study, we determined the expression of BDNF in different perivascular adipose tissue (PVAT) depots
Bo Gong et al.
Nature, 631(8020), 415-423 (2024-06-13)
Directed cell migration is driven by the front-back polarization of intracellular signalling1-3. Receptor tyrosine kinases and other inputs activate local signals that trigger membrane protrusions at the front2,4-6. Equally important is a long-range inhibitory mechanism that suppresses signalling at the
Hyo Jeong Kim et al.
Frontiers in neuroscience, 15, 725398-725398 (2021-10-26)
Rett syndrome (RTT) is a severe X-linked dominant neurodevelopmental disorder caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene; MeCP2 regulates the expression of brain-derived neurotrophic factor (BDNF) and increasing BDNF levels ameliorates RTT symptoms. However, the clinical application

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico